Pathophysiology of bone loss in patients receiving anticonvulsant therapy.
Many studies have shown that patients taking antiepileptic drugs (AEDs) are at increased risk for metabolic bone disease and low bone mineral density. Although early reports of bone disease in patients with epilepsy often involved institutionalized patients, who may be at risk because of lack of physical activity, reduced sunlight exposure, and poor nutrition, low bone density has also been reported in well-nourished, ambulatory outpatients with epilepsy. Traditionally, attention to the problem of AED-induced bone loss has been focused on those drugs that induce the hepatic cytochrome P450 enzyme system, thereby increasing the metabolism of vitamin D. However, the mechanisms of AED-induced bone loss appear to be multiple, and all types of AEDs are potentially implicated. Besides hepatic enzyme induction, mechanisms may include direct effects of AEDs on bone cells, resistance to parathyroid hormone, inhibition of calcitonin secretion, and impaired calcium absorption. An understanding of bone biology and the pathophysiology of bone loss can aid in the identification and monitoring of patients at risk and in the planning of appropriate prophylactic and therapeutic measures, by which most of the morbidity associated with AED-induced bone loss can be prevented.
Fitzpatrick
Lorraine A
LA
Division of Endocrinology, Diabetes, Metabolism, Nutrition, and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. fitz@mayo.edu
D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D002116:Calcitonin / Q000172:deficiency; D002118:Calcium / Q000378:metabolism; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000139:chemically induced / Q000503:physiopathology; D006996:Hypocalcemia / Q000139:chemically induced / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D010018:Osteomalacia / Q000139:chemically induced* / Q000503:physiopathology*; D010024:Osteoporosis / Q000139:chemically induced* / Q000503:physiopathology*; D010281:Parathyroid Hormone / Q000502:physiology; D014808:Vitamin D Deficiency / Q000139:chemically induced / Q000503:physiopathology
D000927:Anticonvulsants; D010281:Parathyroid Hormone; D002116:Calcitonin; D003577:Cytochrome P-450 Enzyme System; D002118:Calcium